Literature DB >> 9755414

Oocyte maturation.

A Trounson1, C Anderiesz, G M Jones, A Kausche, N Lolatgis, C Wood.   

Abstract

Primary oocytes recovered from small and growing follicles of > or = 3 mm in the ovaries of untreated women, can be matured in vitro, will fertilize and develop in vitro, and when transferred to the patient, develop to term. However, the implantation rate of cleaved embryos has been disappointingly low and when embryos are allowed to develop beyond the 4-cell in vitro, retardation of development and blockage is frequently observed, with relatively few embryos developing to blastocysts. We have devised new culture systems for human embryos to enable high rates of development of in-vivo matured oocytes to blastocysts within 5-6 days of culture, and high implantation rates of these blastocysts when they are transferred to the patients' uterus. These culture systems are now being used for in-vitro matured oocytes. In order to determine whether embryo developmental competence could be improved, a number of factors were examined. Treatment of patients with pure follicle stimulating hormone (FSH) early in the follicular phase, or treatment with oestrogen prior to oocyte recovery, had no apparent effect on any parameters of oocyte developmental competence. There was no indication that a medium made specifically for human oocyte maturation improved oocyte developmental competence. Nuclear and cytoplasmic changes in oocytes matured in vitro appear to be similar to that in vivo, although some lack of synchronization in completing maturation is evident. It is possible that follicles of < 10 mm diameter in the human contain developmentally-incompetent oocytes. However, the development to term and birth of normal babies from germinal vesicle stage oocytes recovered from small follicles and matured in vitro, suggests that further research will identify the factors necessary to improve embryo developmental competence. The application of immature oocyte collection (IOC) and in vitro maturation (IVM) as an alternative to ovulation stimulation with high doses of gonadotrophins for in-vitro fertilization (IVF), remains a priority for research in human medicine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755414     DOI: 10.1093/humrep/13.suppl_3.52

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  14 in total

1.  Correlation between human follicular diameter and oocyte outcomes in an ICSI program.

Authors:  Anusorn Triwitayakorn; Somchai Suwajanakorn; Kamthorn Pruksananonda; Wisan Sereepapong; Vichuda Ahnonkitpanit
Journal:  J Assist Reprod Genet       Date:  2003-04       Impact factor: 3.412

Review 2.  Controversies in IVM.

Authors:  Shauna Leigh Reinblatt; Weon-Young Son; Einat Shalom-Paz; Hananel Holzer
Journal:  J Assist Reprod Genet       Date:  2011-05-10       Impact factor: 3.412

3.  Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.

Authors:  Rubens Fadini; Ruggero Comi; Mario Mignini Renzini; Giovanni Coticchio; Marilena Crippa; Elena De Ponti; Mariabeatrice Dal Canto
Journal:  J Assist Reprod Genet       Date:  2011-06-15       Impact factor: 3.412

4.  Effects of retinoic acid on maturation of immature mouse oocytes in the presence and absence of a granulosa cell co-culture system.

Authors:  Leila Sadat Tahaei; Hussein Eimani; Poopak Eftekhari Yazdi; Bita Ebrahimi; Rouhollah Fathi
Journal:  J Assist Reprod Genet       Date:  2011-06-17       Impact factor: 3.412

5.  Reduced uterine receptivity for mouse embryos developed from in-vitro matured oocytes.

Authors:  Yu-Hung Lin; Ching-Yen Tsai; Lee-Wen Huang; Kok-Min Seow; Jiann-Loung Hwang; Chii-Ruey Tzeng
Journal:  J Assist Reprod Genet       Date:  2014-10-08       Impact factor: 3.412

6.  Parthenogenic blastocysts derived from cumulus-free in vitro matured human oocytes.

Authors:  Sohyun L McElroy; James A Byrne; Shawn L Chavez; Barry Behr; Aaron J Hsueh; Lynn M Westphal; Renee A Reijo Pera
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

7.  What is the optimal threshold of serum Anti-Müllerian hormone (AMH) necessary for IVM treatments?

Authors:  Alon Kedem; Gil M Yerushalmi; Ettie Maman; Rina Hemi; Mirit Hanochi; Ariel Hourvitz
Journal:  J Assist Reprod Genet       Date:  2013-04-23       Impact factor: 3.412

8.  Human therapeutic cloning (NTSC): applying research from mammalian reproductive cloning.

Authors:  Andrew J French; Samuel H Wood; Alan O Trounson
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

9.  Comparative maturation of cynomolgus monkey oocytes in vivo and in vitro.

Authors:  Hang Yin; Diane M Duffy; Roger G Gosden
Journal:  Reprod Biol Endocrinol       Date:  2006-04-04       Impact factor: 5.211

Review 10.  Post-Translational Modifications in Oocyte Maturation and Embryo Development.

Authors:  Yu Wu; Mo Li; Mo Yang
Journal:  Front Cell Dev Biol       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.